Target intelligence / Profile preview

ST3 beta-galactoside alpha-2,3-sialyltransferase 4 messenger RNA 3' untranslated region (ST3GAL4 mRNA 3'UTR) (ST3GAL4 mRNA 3'UTR)

Target
ST3GAL4 mRNA 3'UTR
Molecular classification
Messenger RNA, Untranslated region, RNA, Other
01

Overview

The ST3GAL4 mRNA 3' untranslated region (3'UTR) is a critical regulatory segment of the messenger RNA encoding the ST3 beta-galactoside alpha-2,3-sialyltransferase 4 enzyme. This region contains binding sites for microRNAs (miRNAs) and RNA-binding proteins that modulate the stability and translation efficiency of the ST3GAL4 transcript. In various cancers, including gastric and pancreatic cancer, the dysregulation of this UTR-mediated control leads to the overexpression of ST3GAL4, which in turn increases the synthesis of sialyl-Lewis X (sLeX) epitopes on the cell surface. These epitopes are essential for selectin-mediated adhesion and subsequent metastatic spread. Consequently, the ST3GAL4 mRNA 3'UTR is an emerging therapeutic target for RNA-based interventions, such as miRNA mimics (e.g., miR-370) or antisense oligonucleotides, aimed at reducing enzyme levels to inhibit tumor progression and metastasis. Beyond oncology, the regulation of this region is also implicated in inflammatory conditions like osteoarthritis and the synthesis of receptors for avian influenza viruses [PubMed: 33080315, NIH]. Therapeutic strategies targeting this UTR aim to restore normal sialylation patterns and prevent pathological cell-cell interactions. Challenges in targeting this region include ensuring specificity to avoid off-target RNA interactions and achieving effective delivery to target tissues.

Other names
ST3Gal IV mRNA 3'UTRSIAT4C mRNA 3'UTRSTZ mRNA 3'UTRNANTA3 mRNA 3'UTRSAT3 mRNA 3'UTRCGS23 mRNA 3'UTRAlpha 2,3-ST 4 mRNA 3'UTR
02

Mechanism of action

Binding to the 3'UTR sequence to induce mRNA degradation or inhibit translation, thereby reducing the expression of the ST3GAL4 enzyme.

03

Biological functions

Regulation of mRNA stabilityTranslational regulationPost-transcriptional gene silencingSialylationImmune responseOther
04

Disease associations

CancerInflammationInfectionOther
05

Safety considerations

Off-target RNA bindingAlteration of systemic sialylationPotential impact on platelet clearance and hemostasisDelivery challenges for RNA-based therapeutics
06

Interacting drugs

miR-370 mimic

3 more in the full profile.

07

Biomarkers

ST3GAL4 mRNA expressionSialyl-Lewis X (sLeX) levelsmiR-370 expressionmiR-193b expression

Beyond the preview

Go deeper on ST3 beta-galactoside alpha-2,3-sialyltransferase 4 messenger RNA 3' untranslated region (ST3GAL4 mRNA 3'UTR) (ST3GAL4 mRNA 3'UTR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST3 beta-galactoside alpha-2,3-sialyltransferase 4 messenger RNA 3' untranslated region (ST3GAL4 mRNA 3'UTR) (ST3GAL4 mRNA 3'UTR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call